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Except for one case, spearman’s rank correlation coefﬁcient
between instruments was high (rho > 0.70). Furthermore, test-
retest reliability in terms of ICC(3,1) was good for all instru-
ments, i.e., 0.98 (95% CI, 0.82–0.99) for the BMJ check-list,
0.96 (95% CI, 0.75–0.99) for the CHEC list, and 0.95 (95% CI,
0.75–0.99) for the QHES instrument. Yet, they were poor agree-
ment between the two examiners (kappa < 0.40 for most items
and ICC(2,1) < 0.5). CONCLUSION: Findings highlight the
subjective character of the assessment. Results are not inﬂuenced
by the instrument used but more by the assessor. It is thus
essential to perform quality analysis of economic evaluations by
at least two experts and to base the ﬁnal scoring on a consensus.
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OBJECTIVES: Measuring the QALY beneﬁts of new health inter-
ventions is critically dependent on the values of the quality-
adjustment index—putting the “Q” in QALYs. For many health-
related quality of life indexes, including EQ-5D, there aremultiple
options when selecting the value set for use in a given application.
For the purposes of health technology assessment in England and
Wales the National Institute for Health and Clinical Excellence
has published guidance thatwhen conducting the appraisal of new
health technologies the values of the relevant population should be
applied. However, the standard set of values used to derive the
EQ-5Dindex were collected from a national UK population survey
that included Scottish respondents whose health care system is
organised and funded separately from the NHS in England and
Wales. This paper reworks the original UK survey data and
presents a new set of weights for EQ-5D recalibrated using the
appropriate population values. METHODS: The Measurement
and Valuation of Health (MVH) survey methods have been fully
described elsewhere. A total of 3395 individuals used ranking,
rating and TTO methods to value a subset of 15 EQ-5D health
states. A total of 360 of these respondents were citizens of
Scotland. RESULTS: Scottish respondents reported similar health
status compared to their English counterparts. However Scottish
TTO values were systematically higher for 23/26 mild-moderate
states and 16/17 states worse than dead were lower than English
values. The Scottish data were removed from the MVH dataset
and a new OLS regression model was constructed (r2 = 0.492).
70% of values for EQ-5D health states in the revised model differ
by more than 0.05 when compared with the original MVH values
currently applied by NICE. The impact of applying these weights
varies with the severity of the condition under review. CONCLU-
SION: The use of existing MVH weights appears contraindicated
if English QALYs are required.
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OBJECTIVES: Within the Dutch guidelines for treatment of
Type 2 Diabetes Mellitus (T2DM), the target-value of HbA1c has
been set at <7%. The aim of this study was to investigate the
relationship between persistence with oral antidiabetic drug
(OAD-)treatment and HbA1c goal-attainment in daily clinical
practice. METHODS: From the PHARMO record linkage
system, comprising among others, linked drug-dispensing,
clinical laboratory, and hospital data for >2.3 million subjects
in The Netherlands, new users of OADs were identiﬁed in
the period 1999–2005. Patients who started on monotherapy
with metformin, a sulphonylurea (SU), or a thiazolidinedione
(TZD), or on combination therapy with metformin+SU, or
metformin+TZD, with baseline HbA1c °Ý7% and at least one
HbA1c-measurement in the period of 6–12 months after
treatment-onset, were included in the study-cohort. Persistence
with OAD-treatment in the ﬁrst year of treatment was determined
using the method of Catalan, and was deﬁned as the duration of
the ﬁrst treatment-episode in days. In case the ﬁrst treatment-
episode overlapped with the date of a HbA1c-measurement, a
patient was considered persistent at that measurement. Patients
with HbA1c <7% were deﬁned at goal. RESULTS: The study
cohort included 2023 patients. Three-quarters (1512 patients)
were persistent with any OAD at the time of ﬁrst HbA1c-
measurement in the time-period of 6–12 months after OAD-start:
of these, 861 (57%) were at goal. Of the 511 patients who were
non-persistent with any OAD at that time, 239 (47%) were at
goal. Non-persistent patients were about 20% less likely to be at
goal (RR-adj: 0.82; 95% CI: 0.74–0.91), compared to persistent
users of any OAD. CONCLUSION: Non-persistent use of OADs
leads to a 20% decreased chance of HbA1c goal-attainment in
daily clinical practice. This effect of non-persistence seems
modest, but represents a very large number of patients, in whom
OAD-use might be better controlled.
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OBJECTIVES: Compare the risk-beneﬁt preferences of patients,
parents of juvenile patients and gastroenterologists for Crohn’s
disease (CD) treatments. METHODS: Panels of CD patients,
parents of juvenile patients and gastroenterologists completed a
series of choice-format conjoint trade-off tasks with varying
efﬁcacy and risk levels. Parents evaluated treatments for their
child, gastroenterologists evaluated treatments for three patients
(young, middle-aged, elderly). Treatment attributes included
daily symptom severity and activity limitations, potential for CD
complications, time between ﬂare-ups, systemic steroid use, and
three SAE mortality risks: serious infection (SI), progressive mul-
tifocal leukoencephalopathy (PML) and lymphoma. Preference
estimates were used to calculate the annual SAE-speciﬁc
maximum acceptable risk (MAR) for various levels of clinical
beneﬁt. RESULTS: 342 patients, 105 parents of juvenile patients,
and 315 gastroenterologists provided usable data for analysis.
For all respondent groups improvement in daily symptom severity
was the most important factor in treatment preferences and risk
tolerance was greater for treatments with better clinical beneﬁts.
Physicians had lower MARs for young patients and higher MARs
for the elderly. For middle-aged patients, gastroenterologists’
MAR ranged from 0.16% to 0.76% for death or disability from
PML, 0.24% to 0.58% for death from SI, and 0.13% to 0.81%
for death due to lymphoma. Patients’ preferences are similar to
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